Navigation Links
Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
Date:1/8/2008

stry-leading PEGylation and pulmonary drug development platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements that reflect the company's current views as to the value, relative competitive position, and application of the company's technology platforms, and statements regarding the progress, potential, and future clinical plans for the company's proprietary product candidates in clinical and preclinical development. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and pre-clinical development and the risk of failure is high and can unexpectedly occur at any stage, (ii) the timing or success of the commencement or conclusion of planned clinical trials is subject to a number of uncertainties including but not limited to clinical design, patient enrollment, regulatory requirements and clinical outcomes, (iii) the company's or its partner's success in meeting minimum clinical end points and obtaining regulatory approvals for product candidates, (iv) the company may not successfully complete new collaborative partnerships with respect to its product candidates, or if any partnerships the company does negotiate do not include sufficiently favorable commercial terms, the company may not receive an adequate return on these investments and our results of operations and financial condition would suffer, (v) the company's patent applications for its proprietary or
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
2. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
7. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "China Orthopedic Instrument Industry Report, 2014-2017" ... accelerated aging population and rising proportion of reimbursement for ... been effectively released, with its scale presenting a CAGR ... joint products are three product segments of orthopedic instruments ...
(Date:8/29/2014)... Research and Markets  has announced the addition ... report to their offering. The Central ... the largest segments of pharmaceuticals industry. The numbers of CNS ... therapies were unable to meet the market requirements. There has ... disorder, especially over the past two decades. The market for ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... , EMERYVILLE, Calif., Nov. 5 Bionovo, Inc. (Nasdaq: ... focused on the unmet needs in women,s health and ... for the three months ended September 30, 2009. , ... 2009, Bionovo successfully completed a public offering and issued ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be ... Phoenix, Arizona on Wednesday, November 11, 2009 at 10:00 a.m. ... president of finance and chief financial officer at Amylin Pharmaceuticals, ... of the presentation will be webcast and a recording will ...
Cached Medicine Technology:Bionovo Announces Third Quarter 2009 Highlights and Financial Results 2Bionovo Announces Third Quarter 2009 Highlights and Financial Results 3Bionovo Announces Third Quarter 2009 Highlights and Financial Results 4Bionovo Announces Third Quarter 2009 Highlights and Financial Results 5Bionovo Announces Third Quarter 2009 Highlights and Financial Results 6Bionovo Announces Third Quarter 2009 Highlights and Financial Results 7Bionovo Announces Third Quarter 2009 Highlights and Financial Results 8Bionovo Announces Third Quarter 2009 Highlights and Financial Results 9
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... September 01, 2014 An operating theatre ... hospital for performing surgical operations. An operating room comprises ... surgical booms, operating room lights, imaging displays as well ... report by Transparency Market Research, a U.S.-based market research ... reach USD 4.5 billion by 2019. , According ...
(Date:9/1/2014)... Monday 1 September 2014: Daily fruit consumption cuts ... 40%, according to research presented at ESC Congress today ... from the seven year follow-up study of nearly 0.5 ... the more fruit people ate, the more their risk ... ischaemic heart disease (IHD) and stroke, is the leading ...
(Date:9/1/2014)... 2014 Bioinformatics refers to an ... biological and genetic data. A major part of ... software tools to generate and process useful biological ... biological computation. While bioinformatics simply makes use of ... its related concepts, biological computation refers to the ...
(Date:9/1/2014)... Vegas, NV (PRWEB) September 01, 2014 ... entrepreneurs and online marketers that was developed to automate ... has caught the attention of Shane Michaels, prompting an ... established entrepreneur, the daily duty of managing all of ... business can be quite overwhelming,” reports Michaels. “That’s why ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... and offers a challenge to businessesCHICAGO, April 2 ... Easter Seals and Special Olympics launched the grocery retailer,s ... D.C., by challenging employers to tap into what they ... and willing to work. Each April, Safeway stores raise ...
... Radianse Smart Sense technology assures hospital will know where ... way to see, analyze and respond to influenza transmission ... the Emergency Department (ED) of Emory University ... system (RTLS) with Smart Sense technology to know early ...
... WESTLAKE VILLAGE, Calif., April 2 Health plan ... for small employers are considerably less satisfied with ... members who work for larger organizations, according to ... Health Insurance Plan Study(SM) released today.(Logo: ...
... 2009 -- More than 6,000 internists (adult medicine ... will meet in Philadelphia for Internal Medicine 2009, ... of Physicians (ACP), April 23 - 25 (Thursday ... ACP is the largest specialty organization devoted exclusively ...
... 2 The following is a statement from Jeff Levi, ... response to the release of the new report Beyond ... Robert Wood Johnson Foundation Commission to Build a Healthier America:"Every ... he or she can be. And every community should ...
... Pharmaceutical Laboratories, Ltd. (NYSE AMEX: CPD ) ... Industries Ltd. (Sun Pharma), immediately following Sun Pharma,s recently ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... in patients 10 years of age and older with ...
Cached Medicine News:Health News:Safeway Slated to Top $100 Million Contribution Mark to Easter Seals and Families Living with Autism and Other Disabilities with Launch of Fundraising Campaign 2Health News:Safeway Slated to Top $100 Million Contribution Mark to Easter Seals and Families Living with Autism and Other Disabilities with Launch of Fundraising Campaign 3Health News:Safeway Slated to Top $100 Million Contribution Mark to Easter Seals and Families Living with Autism and Other Disabilities with Launch of Fundraising Campaign 4Health News:Radianse Announces Real-Time Tracking of Emory ED Staff and Patients to Trace and Contain Infectious Disease Spread 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans is Notably Lower among Individual Purchasers and Small Employer Members 6Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 2Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 3Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 4Health News:From the ethics of Dr. Frankenstein to preventing cardiovascular disease 5Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets 2
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Soft, autoclavable, and without conformer....
Size: Small. 20.50 mm by 22.00 mm. Clear lucite. Supplied sterile....
... x 100 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Medicine Products: